Psybio Therapeutics Corp Stock Today
| PSYBF Stock | USD 0.0001 0.00 0.00% |
PerformanceVery Weak
| Odds Of DistressBelow Average
|
PsyBio Therapeutics is trading at 1.0E-4 as of the 23rd of March 2025. This is a No Change since the beginning of the trading day. The stock's lowest day price was 1.0E-4. PsyBio Therapeutics has about a 29 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 23rd of December 2024 and ending today, the 23rd of March 2025. Click here to learn more.
PsyBio Therapeutics Corp., a biotechnology company, focuses on the research, development, and commercialization of psychedelic-inspired regulated medicines for the treatment of mental health and other disorders in the United States. Psybio Therapeautics operates under Biotechnology classification in the United States and is traded on OTC Exchange. The company has 80.85 M outstanding shares. More on PsyBio Therapeutics Corp
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
PsyBio Pink Sheet Highlights
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
PsyBio Therapeutics Corp [PSYBF] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.94 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate PsyBio Therapeutics's market, we take the total number of its shares issued and multiply it by PsyBio Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. PsyBio Therapeutics Corp classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 80.85 M outstanding shares.
PsyBio Therapeutics Corp has accumulated about 911.83 K in cash with (6.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check PsyBio Therapeutics Probability Of Bankruptcy
Ownership AllocationPsyBio Therapeutics owns a total of 80.85 Million outstanding shares. PsyBio Therapeutics has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check PsyBio Ownership Details
PsyBio Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in PsyBio Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Financial Widgets Now
Financial WidgetsEasily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
| All Next | Launch Module |
PsyBio Therapeutics Corporate Management
| Andrew Jones | Inventor Board | Profile | |
| Ross Carmel | Chief Director | Profile | |
| Noah Davis | S CFO | Profile | |
| Evan Levine | CEO CoFounder | Profile | |
| MBA MBE | Chief Officer | Profile |
Other Information on Investing in PsyBio Pink Sheet
PsyBio Therapeutics financial ratios help investors to determine whether PsyBio Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PsyBio with respect to the benefits of owning PsyBio Therapeutics security.